恒生创新药ETF(159316)冲击3连涨，最新规模近20亿元再创新高，机构：创新药仍将是全年医药板块的投资主线

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCID) increased by 0.74%, while the Hang Seng Innovative Drug ETF (159316) rose by 1.10%, marking a three-day consecutive increase [1] - As of September 1, the latest scale of the Hang Seng Innovative Drug ETF reached 1.968 billion, a record high since its establishment [1] - In the past five trading days, there were net inflows into the Hang Seng Innovative Drug ETF on four occasions, totaling 362 million [1] Group 2 - The National Medical Products Administration indicated that the "14th Five-Year Plan" has seen significant policy dividends for the pharmaceutical industry, with 210 innovative drugs and 269 innovative medical devices approved, showing a trend of accelerated growth [1] - China's biopharmaceutical market has become the second largest globally, with approximately 30% of the world's innovative drugs under research [1] - The total amount of external authorization for innovative drugs in the first half of 2025 approached 66 billion, reflecting increasing global recognition of Chinese innovative drugs [1] Group 3 - According to Zhongtai Securities, the pharmaceutical industry's fundamentals improved significantly in Q2 2025, with a notable reduction in the decline of revenue and profit, particularly in the chemical preparation sector, which saw a 11.5% year-on-year increase in net profit [2] - Despite overall pressure on the pharmaceutical sector in the first half of the year, innovative drugs remain the most promising sub-sector with clear growth potential [2] - The upcoming WCLC 2025 conference is expected to disclose multiple innovative drug clinical data, serving as a catalyst for the sector [2] Group 4 - The Hang Seng Innovative Drug ETF closely tracks the Hang Seng Innovative Drug Index, which reflects the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [2] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCIHKI) is the only "100% purity" innovative drug index in the market, focusing on companies holding core patents and directly participating in innovative drug R&D and commercialization [2]